GoldnBoy replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
More good news today
Monday February 27 2017 - News Release
Mr. Chris Bunka reports
LEXARIA RECEIVES NOTICE OF ITS FIRST PATENT TO BE GRANTED IN AUSTRALIA FOR CANNABINOID INFUSED EDIBLES
Lexaria Bioscience Corp. has received a notice of acceptance from the Australian Patent Office that Lexaria's Australian patent application 2015274698 has been accepted with a patent issuance date expected in June, 2017. This establishes Lexaria's first successful acceptance for patent issuance outside of the United States, in what the company expects will be a series of successful international patent awards.
The notice of acceptance covers Lexaria's patent application entitled "Food and beverage compositions infused with lipophilic active agents and methods of use thereof," which has been accepted with the same set of claims previously issued in U.S. patent No. 9,474,725 specific to non-psychoactive cannabinoids.
Lexaria is very pleased with the rapid advancement of its patent claims by the Australian Patent Office and notes Australia's recent federal legislative success in opening the medical cannabis market. Like Canada, the medical cannabis market in Australia is federally legal.
"Lexaria's technology is needed not just in the U.S. but throughout the global cannabis sector, which is why we have patent applications in place in 42 countries around the world," said Chris Bunka, chief executive officer. "Our international applications offer the safety of unparalleled diversification to our supporters that even individual national market leaders cannot offer."
The accepted patent application includes a series of Lexaria's method claims for combining non-psychoactive cannabinoid lipophilic active agents together with a bioavailability and taste-enhancing oil by way of dehydration or lyophilization, and doing so in contact with a food product substrate material. Lexaria still has a number of additional patent applications undergoing review by the U.S. Patent and Trademark Office and patent application continuations planned in order to further broaden its expected set of compositional and method patent claims regarding the technology for application with other molecules such as psychoactive cannabinoids, vitamins, non-steroidal anti-inflammatory drugs and nicotine.
The company continues to thank its many supporters who have contributed to its intellectual property success.
lynnsa10 replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Great news today
2017-02-08 10:14 ET - News Release
Mr. Chris Bunka reports
LEXARIA SIGNS MASTER COLLABORATIVE RESEARCH AGREEMENT
Lexaria Bioscience Corp., through its wholly owned Canadian subsidiary Lexaria Canpharm Corp., has signed and entered a master collaborative research agreement with the National Research Council of Canada (NRC) to investigate technical aspects and new opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions.
Lexaria believes that results from this scientific collaboration could motivate licence adoption of Lexaria's patented flavour masking and nutrient delivery enhancement technology, including but not limited to the vitamin, pain reliever and nicotine sectors. Lexaria's technology is patented in the United States, and patent pending in Canada and in 41 other countries around the world.
Under the agreement, Lexaria and the NRC will both provide up to $125,000 for this research, a total investment of up to $250,000. The master research agreement has an 18-month term, during which a number of shorter-term studies will be undertaken. The collaboration will investigate and define the chemical nature of the molecular association that Lexaria's patented technology is believed to effectuate between lipophilic active agents and fatty acids as solubility and bioavailability enhancing agents. Effective delivery of lipophilic active agents spans across industry sectors such as food, vitamins, pharmacy and more, which are multibillion-dollar opportunities.
Prospective lipophilic active agents to be investigated under the research agreement include cannabinoids (such as cananbidiol (CBD) and tetrahydrocannabinol (THC), fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and nicotine, as described in Lexaria's issued and pending patent applications, as well as potentially other high-value bioactives to be determined. The research agreement also provides for possible licensing of any arising, non-competing Lexaria intellectual property to the NRC or its sublicensees on terms to be defined in the future as applicable.
"This co-funded research agreement with the National Research Council of Canada is a major achievement for us," said John Docherty, president of Lexaria. "Having the privilege to work within their high-calibre facilities alongside their expert scientists will allow Lexaria to further advance the characterization and commercial potential of its technology in the fastest way possible for a company of our size. Furthermore, the fact that they have a level 2 dealer's licensed facility in Canada, in which some of this work can be conducted, is of particular importance, thereby allowing us to advance research on controlled substances with ease."
"The National Research Council's support in the development and commercialization of our technology is highly validating for our company," said Chris Bunka, chief executive officer of Lexaria. "Positive findings from this joint investigation will be of tremendous value to Lexaria in order to broaden the scientific understanding of our intellectual property suite and support our abilities to attract additional strategic licensees across the greater therapeutic foods, dietary supplements and pharmaceutical sectors."
Lexaria intends to commercialize its technology for widespread use by markets throughout the world, including over-the-counter pain remedy sector, vitamins and food supplements, and even the nicotine industries and more. To achieve that, this undertaking of fundamental research will enhance the company's ability to enter into these distinct market sectors.
alexgreat replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Glad to see a topic started.
Looks like red tape in California will take a while
“Being blunt, there is no way the state of California can meet all of the deadlines before we go live on January 1, 2018,” state Sen. Mike McGuire, a dad-joke caliber pun-slinging Sonoma County Democrat, told the Sacramento Bee. “We are building the regulatory system for a multibillion dollar industry from scratch.”
Let’s forget for a second that none of what McGuire just said is true.
Even if Colorado—and then Washington, then Oregon and then Alaska—hadn’t provided California with a model to follow, the state in 2015 passed regulations for medical marijuana. And Prop. 64 was specifically modeled after the Medical Marijuana Regulation and Safety Act, signed into law by Gov. Jerry Brown in fall 2015.